1-855-378-42281-855-378-4228
One of the out-patient rehab alternatives for people in Elkwood who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Some clinics and doctors are authorized to give certain medications to opioid dependent people, many of which are opioids themselves and are addictive. With low doses the client does not experience being high but also does not have severe cravings and is not in opioid withdrawal. Methadone is the first med used for this reason, but there are a few more options currently to select from.
Methadone is an opiate and is meant to be taken at an outpatient medical center certified to administer the med, which is taken on a daily basis as a pill or liquid. The price of the med is about one hundred and fifty dolloars a month. Buprenorphine is also an opioid based drug, and is in pill form often taken every other day. But different from Methadone which can only be dispensed in highly well-regulated medical centers, Buprenorphine can be prescribed and dispensed in doctor's offices. The cost monthly of buprenorphine is about three hundred dollars /month for the generic of the drug. There is also a type of buprenorphine that contains naloxone, which is a med that reverses the effects of opiates. An individual consuming this version of the drug, AKA Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It is also taken daily, and is priced approximately $450 a month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other medications aforementioned it is an opiate blocker and isn't an opioid. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, the drug prevents someone from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Rehabilitation Facilities In Elkwood, Click Here.
